文献速递膀胱癌与上尿路尿路上皮癌

BOXIT:塞来昔布联合标准治疗非肌层浸润性膀胱癌的III期随机对照试验

BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
PubMed 文献 · Eur Urol · 2018-09-29

BOXIT是一项双盲III期随机对照试验,纳入472例中危或高危非肌层浸润性膀胱癌患者,比较塞来昔布200mg每日两次与安慰剂治疗2年的效果。中位随访44个月,3年无复发生存率塞来昔布组68%对安慰剂组64%(HR 0.82,95%CI 0.60-1.12,p=0.2),差异无统计学意义。亚组分析提示pT1患者塞来昔布组复发时间延长(HR 0.53,95%CI 0.30-0.94),但塞来昔布组严重心血管事件发生率更高(5.2%对1.7%)。

要点

  • 塞来昔布未显著降低中高危NMIBC总体复发风险。
  • pT1亚组塞来昔布可能延迟复发,但需进一步验证。
  • 塞来昔布组严重心血管事件发生率数值更高,不支持常规使用。

核心结论

  • BOXIT试验未显示塞来昔布降低中危或高危NMIBC患者的复发风险。
  • 塞来昔布与pT1 NMIBC患者复发时间延迟相关,但心血管事件风险增加不支持其使用。

研究设计与样本

  • BOXIT(CRUK/07/004,ISRCTN84681538)为双盲、III期、随机对照试验。
  • 患者按1:1随机接受塞来昔布200mg每日两次或安慰剂治疗2年。
  • 中危NMIBC患者推荐接受六周丝裂霉素C灌注;高危患者接受六周卡介苗及维持治疗。
  • 共随机472例患者(236:236),主要终点为复发时间,采用意向性分析。

主要发现

  • 中位随访44个月(四分位距36-57),3年无复发率塞来昔布组68%(95%CI 61-74%),安慰剂组64%(95%CI 57-70%),HR 0.82(95%CI 0.60-1.12),p=0.2。
  • 高危NMIBC亚组HR 0.77(95%CI 0.52-1.15),p=0.2;中危亚组HR 0.90(95%CI 0.55-1.48),p=0.7。
  • pT1 NMIBC患者中,塞来昔布组复发时间较安慰剂组延长,HR 0.53(95%CI 0.30-0.94),交互检验p=0.04。
  • 高危患者3年进展率塞来昔布组10%(95%CI 6.5-17%),安慰剂组9.7%(95%CI 6.0-15%)。
  • 严重心血管事件发生率塞来昔布组5.2%,安慰剂组1.7%,差异+3.4%(95%CI -0.3%至7.2%),p=0.07。

临床怎么用

  • 不推荐在中危或高危NMIBC标准治疗中常规加用塞来昔布以降低复发风险。
  • 对于pT1 NMIBC患者,塞来昔布延迟复发的信号需权衡心血管风险,暂不作为临床常规推荐。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patients receiving standard treatment. DESIGN, SETTING, AND PARTICIPANTS: BOXIT (CRUK/07/004, ISRCTN84681538) is a double-blinded, phase III, randomised controlled trial. Patients aged ≥18 yr with intermediate- or high-risk NMIBC were accrued across 51 UK centres between 1 November 2007 and 23 July 2012. INTERVENTION: Patients were randomised (1:1) to celecoxib 200mg twice daily or placebo for 2 yr. Patients with intermediate-risk NMIBC were recommended to receive six weekly mitomycin C instillations; high-risk NMIBC cases received six weekly bacillus Calmette-Guérin and maintenance therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was time to disease recurrence. Analysis was by intention to treat. RESULTS AND LIMITATIONS: A total of 472 patients were randomised (236:236). With median follow-up of 44 mo (interquartile range: 36-57), 3-yr recurrence-free rate (95% confidence interval) was as follows: celecoxib 68% (61-74%) versus placebo 64% (57-70%; hazard ratio [HR] 0.82 [0.60-1.12], p=0.2). There was no difference in high-risk (HR 0.77 [0.52-1.15], p=0.2) or intermediate-risk (HR 0.90 [0.55-1.48], p=0.7) NMIBC. Subgroup analysis suggested that time to recurrence was longer in pT1 NMIBC patients treated with celecoxib compared with those receiving placebo (HR 0.53 [0.30-0.94], interaction test p=0.04). The 3-yr progression rates in high-risk patients were low: 10% (6.5-17%) and 9.7% (6.0-15%) in celecoxib and placebo arms, respectively. Incidence of serious cardiovascular events was higher in celecoxib (5.2%) than in placebo (1.7%) group (difference +3.4% [-0.3% to 7.2%], p=0.07). CONCLUSIONS: BOXIT did not show that celecoxib reduces the risk of recurrence in intermediate- or high-risk NMIBC, although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. The increased risk of cardiovascular events does not support the use of celecoxib. PATIENT SUMMARY: Celecoxib was not shown to reduce the risk of recurrence in intermediate- or high-risk non-muscle-invasive bladder cancer (NMIBC), although celecoxib was associated with delayed time to recurrence in pT1 NMIBC patients. The increased risk of cardiovascular events does not support the use of celecoxib.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kelly JD, Tan WS, Porta N, et al. BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). Eur Urol. 2018. PMID: 30279015. doi:10.1016/j.eururo.2018.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。